Publicaciones en las que colabora con Ana Isabel Bocanegra (11)

2024

  1. PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

    EMBO Molecular Medicine, Vol. 16, Núm. 8, pp. 1791-1816

2023

  1. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

    EMBO Reports, Vol. 24, Núm. 8

2022

  1. Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

    Cancers, Vol. 14, Núm. 16

  2. Clinical landscape of LAG-3-targeted therapy

    Immuno-Oncology and Technology, Vol. 14

  3. The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

    British Journal of Cancer, Vol. 126, Núm. 8, pp. 1168-1177

2021

  1. A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets

    Journal of Personalized Medicine, Vol. 11, Núm. 6

  2. Understanding lag-3 signaling

    International Journal of Molecular Sciences, Vol. 22, Núm. 10

2020

  1. PD-L1 in systemic immunity: Unraveling its contribution to PD-1/PD-L1 blockade immunotherapy

    International Journal of Molecular Sciences, Vol. 21, Núm. 16, pp. 1-17

  2. Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies

    International Journal of Molecular Sciences, Vol. 21, Núm. 7

2019

  1. Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy

    EMBO Molecular Medicine, Vol. 11, Núm. 7

  2. PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer

    International Journal of Molecular Sciences, Vol. 20, Núm. 7